10:08 AM EDT, 07/30/2025 (MT Newswires) -- Vyne Therapeutics ( VYNE ) shares were down more than 71% in early Wednesday trading after the company said its phase 2b trial evaluating repibresib gel in nonsegmental vitiligo did not meet its primary endpoint.

The trial also missed a key secondary endpoint and based on the data, Vyne Therapeutics ( VYNE ) said it will terminate the trial.

Vyne Therapeutics ( VYNE ) said it plans to seek a development and commercialization partner for repibresib.

Price: 0.41, Change: -1.03, Percent Change: -71.74